Table 2.
Detailed GO profiles of the DEGs in UCEC
| ID | Description | GeneRatio | BgRatio | p.adjust | qvalue | geneID | Count | |
|---|---|---|---|---|---|---|---|---|
| BP | GO:0006958 | Complement activation, classical pathway | 38/337 | 137/18670 | 4.55E−31 | 4.27E−31 | IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 38 |
| BP | GO:0002455 | Humoral immune response mediated by circulating immunoglobulin | 38/337 | 150/18670 | 9.97E−30 | 9.37E−30 | IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 38 |
| BP | GO:0006956 | Complement activation | 39/337 | 175/18670 | 2.00E−28 | 1.88E−28 | IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/CFD/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 39 |
| BP | GO:0072376 | Protein activation cascade | 39/337 | 198/18670 | 2.28E−26 | 2.14E−26 | IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/CFD/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 39 |
| BP | GO:0016064 | Immunoglobulin mediated immune response | 39/337 | 218/18670 | 8.39E−25 | 7.88E−25 | IGHV4-31/IGLL1/IL13RA2/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 39 |
| BP | GO:0019724 | B cell mediated immunity | 39/337 | 221/18670 | 1.20E−24 | 1.12E−24 | IGHV4-31/IGLL1/IL13RA2/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 39 |
| BP | GO:0006959 | Humoral immune response | 47/337 | 356/18670 | 2.12E−24 | 1.99E−24 | IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/REG1A/IGHV3-72/CFD/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/KLK7/IGHV3-73/IGLV2-14/IGHV3-13/KLK3/IFNG/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/CAMP/IGLL5/IGLV7-43/IGHV3-30/KLK5/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/CXCL9/IGLC7/IGHV3-74/CXCL13/IGHG2/IGHV2-5 | 47 |
| BP | GO:0006910 | Phagocytosis, recognition | 26/337 | 84/18670 | 9.61E−23 | 9.03E−23 | IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 26 |
| BP | GO:0002920 | Regulation of humoral immune response | 29/337 | 134/18670 | 1.10E−20 | 1.04E−20 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/KLK7/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/KLK5/IGKV1-17/IGKV1D-12/IGKC/IGLC7/CXCL13/IGHG2/IGHV2-5 | 29 |
| BP | GO:0002449 | Lymphocyte mediated immunity | 42/337 | 352/18670 | 5.32E−20 | 5.00E−20 | IGHV4-31/IGLL1/IL13RA2/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/ULBP2/LAG3/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/CD8A/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 42 |
| BP | GO:0002460 | Adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 42/337 | 361/18670 | 1.29E−19 | 1.22E−19 | IGHV4-31/IGLL1/IL13RA2/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/ULBP2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/CD8A/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/CXCL13/IGHG2/IGHV2-5 | 42 |
| BP | GO:0030449 | Regulation of complement activation | 26/337 | 115/18670 | 4.87E−19 | 4.57E−19 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5 | 26 |
| BP | GO:2000257 | Regulation of protein activation cascade | 26/337 | 116/18670 | 5.70E−19 | 5.35E−19 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5 | 26 |
| BP | GO:0050853 | B cell receptor signaling pathway | 27/337 | 129/18670 | 6.11E−19 | 5.74E−19 | IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/CD22/IGHV3-74/IGHG2/IGHV2-5 | 27 |
| BP | GO:0006911 | Phagocytosis, engulfment | 26/337 | 118/18670 | 7.88E−19 | 7.41E−19 | IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 26 |
| BP | GO:0006909 | Phagocytosis | 41/337 | 369/18670 | 1.63E−18 | 1.53E−18 | IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/SIRPG/IGHG4/IGLV2-8/IGHV3-43/APOA1/IGLV6-57/IGHV3-53/IGHV3-72/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IFNG/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 41 |
| BP | GO:0099024 | Plasma membrane invagination | 26/337 | 127/18670 | 5.10E−18 | 4.79E−18 | IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 26 |
| BP | GO:0002377 | Immunoglobulin production | 30/337 | 193/18670 | 2.21E−17 | 2.08E−17 | IGLV5-45/IL13RA2/IGLV8-61/IGKV3D-15/IGLV1-44/IGKV2-30/IGKV5-2/IGLV2-8/IGLV6-57/IGKV1-27/IGLV3-21/IGLV1-36/IGLV2-14/IGLV4-69/IGLV3-16/IGKV1-5/IGKV1D-43/TRDV1/IGLV3-19/IGLV7-43/IGKV1D-13/IGKV1-17/IGKV1D-12/TRAV19/IGKV6D-21/IGKC/TRAV14DV4/CD22/IGLV7-46/IGLV4-60 | 30 |
| BP | GO:0010324 | Membrane invagination | 26/337 | 135/18670 | 2.34E−17 | 2.20E−17 | IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 26 |
| BP | GO:0002433 | Immune response-regulating cell surface receptor signaling pathway involved in phagocytosis | 26/337 | 139/18670 | 4.58E−17 | 4.31E−17 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5 | 26 |
| BP | GO:0038096 | Fc-gamma receptor signaling pathway involved in phagocytosis | 26/337 | 139/18670 | 4.58E−17 | 4.31E−17 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5 | 26 |
| BP | GO:0038094 | Fc-gamma receptor signaling pathway | 26/337 | 142/18670 | 7.34E−17 | 6.90E−17 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5 | 26 |
| BP | GO:0050871 | Positive regulation of B cell activation | 26/337 | 142/18670 | 7.34E−17 | 6.90E−17 | IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 26 |
| BP | GO:0002431 | Fc receptor mediated stimulatory signaling pathway | 26/337 | 145/18670 | 1.22E−16 | 1.14E−16 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5 | 26 |
| BP | GO:0070613 | Regulation of protein processing | 28/337 | 180/18670 | 2.69E−16 | 2.52E−16 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/SPON1/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/CCBE1/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5 | 28 |
| BP | GO:0002440 | Production of molecular mediator of immune response | 34/337 | 286/18670 | 3.04E−16 | 2.86E−16 | IGLV5-45/IL13RA2/IGLV8-61/IGKV3D-15/IGLV1-44/IGKV2-30/IGKV5-2/IGLV2-8/APOA1/IGLV6-57/IGKV1-27/IGLV3-21/IGLV1-36/KLK7/IGLV2-14/IGLV4-69/KLK3/IGLV3-16/IGKV1-5/IGKV1D-43/TRDV1/IGLV3-19/IGLV7-43/IGKV1D-13/KLK5/IGKV1-17/IGKV1D-12/TRAV19/IGKV6D-21/IGKC/TRAV14DV4/CD22/IGLV7-46/IGLV4-60 | 34 |
| BP | GO:1903317 | Regulation of protein maturation | 28/337 | 182/18670 | 3.37E−16 | 3.16E−16 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/SPON1/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/CCBE1/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5 | 28 |
| BP | GO:0002673 | Regulation of acute inflammatory response | 26/337 | 159/18670 | 1.14E−15 | 1.07E−15 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5 | 26 |
| BP | GO:0002429 | Immune response-activating cell surface receptor signaling pathway | 42/337 | 473/18670 | 1.29E−15 | 1.22E−15 | IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/MUCL1/TRBV7-9/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/TRAV19/IGKC/IGLC7/CD22/IGHV3-74/IGHG2/IGHV2-5 | 42 |
| BP | GO:0016485 | Protein processing | 35/337 | 328/18670 | 2.60E−15 | 2.44E−15 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/SPON1/KLK6/IGLV3-21/IGHV4-59/IGHV3-23/PCSK1N/IGLV2-14/IGHV3-13/KLK3/CCBE1/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/KLK1/IGHV3-30/PCSK9/SCG5/IGKV1-17/IGKV1D-12/IGKC/IGLC7/CPXM2/IGHG2/IGHV2-5 | 35 |
| BP | GO:0050864 | Regulation of B cell activation | 27/337 | 184/18670 | 4.15E−15 | 3.90E−15 | IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/CD22/IGHV3-74/IGHG2/IGHV2-5 | 27 |
| BP | GO:0008037 | Cell recognition | 27/337 | 215/18670 | 2.20E−13 | 2.07E−13 | IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/CRTAC1/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 27 |
| BP | GO:0002526 | Acute inflammatory response | 27/337 | 220/18670 | 3.81E−13 | 3.58E−13 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IL1A/IGLC7/IGHG2/IGHV2-5 | 27 |
| BP | GO:0051604 | Protein maturation | 35/337 | 397/18670 | 8.46E−13 | 7.95E−13 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/SPON1/KLK6/IGLV3-21/IGHV4-59/IGHV3-23/PCSK1N/IGLV2-14/IGHV3-13/KLK3/CCBE1/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/KLK1/IGHV3-30/PCSK9/SCG5/IGKV1-17/IGKV1D-12/IGKC/IGLC7/CPXM2/IGHG2/IGHV2-5 | 35 |
| BP | GO:0038095 | Fc-epsilon receptor signaling pathway | 23/337 | 169/18670 | 4.43E−12 | 4.16E−12 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHV2-5 | 23 |
| BP | GO:0042742 | Defense response to bacterium | 31/337 | 330/18670 | 5.32E−12 | 5.00E−12 | IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/KLK7/IGHV3-73/IGHV3-13/KLK3/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/CAMP/IGLL5/IGHV3-30/KLK5/IGHV3-64/IGKC/IGLC7/IGHV3-74/CXCL13/IGHG2/IGHV2-5 | 31 |
| BP | GO:0051251 | Positive regulation of lymphocyte activation | 31/337 | 334/18670 | 7.18E−12 | 6.74E−12 | IGHV4-31/IGLL1/IGHV4-34/IGHM/SIRPG/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/CCL5/TNFSF9/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IFNG/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGF2/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 31 |
| BP | GO:0038093 | Fc receptor signaling pathway | 26/337 | 241/18670 | 2.36E−11 | 2.22E−11 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/IGLC7/IGHG2/IGHV2-5 | 26 |
| BP | GO:0051249 | Regulation of lymphocyte activation | 36/337 | 485/18670 | 5.50E−11 | 5.17E−11 | IGHV4-31/IGLL1/IGHV4-34/IGHM/SOX11/SIRPG/LAG3/IGHG4/FOXN1/IGHV3-43/IGHV3-53/TIGIT/IGHV3-72/CCL5/TNFSF9/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IFNG/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGF2/IGLC7/CD22/IGHV3-74/IGHG2/IGHV2-5 | 36 |
| BP | GO:0050851 | Antigen receptor-mediated signaling pathway | 29/337 | 316/18670 | 5.80E−11 | 5.45E−11 | IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/TRBV7-9/IGHV3-30/IGHV3-64/TRAV19/IGKC/IGLC7/CD22/IGHV3-74/IGHG2/IGHV2-5 | 29 |
| BP | GO:0002696 | Positive regulation of leukocyte activation | 31/337 | 380/18670 | 2.01E−10 | 1.89E−10 | IGHV4-31/IGLL1/IGHV4-34/IGHM/SIRPG/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/CCL5/TNFSF9/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IFNG/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGF2/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 31 |
| BP | GO:0002697 | Regulation of immune effector process | 34/337 | 458/18670 | 2.32E−10 | 2.18E−10 | IL13RA2/IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/ULBP2/LAG3/IGHG4/IGLV2-8/APOA1/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/KLK7/IGLV2-14/IGHV3-13/IFNG/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/KLK5/IGKV1-17/IGKV1D-12/IGKC/IGLC7/CD22/IGHG2/IGHV2-5 | 34 |
| BP | GO:0050867 | Positive regulation of cell activation | 31/337 | 394/18670 | 4.90E−10 | 4.60E−10 | IGHV4-31/IGLL1/IGHV4-34/IGHM/SIRPG/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/CCL5/TNFSF9/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IFNG/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGF2/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 31 |
| BP | GO:0042113 | B cell activation | 27/337 | 310/18670 | 1.14E−09 | 1.07E−09 | IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/CD22/IGHV3-74/IGHG2/IGHV2-5 | 27 |
| BP | GO:0006898 | Receptor-mediated endocytosis | 27/337 | 316/18670 | 1.74E−09 | 1.63E−09 | APOB/IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGLV2-8/APOA1/IGLV6-57/IGHV3-53/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/PCSK9/IGKV1-17/IGKV1D-12/IGKC/AMBP/IGLC7/IGHV2-5 | 27 |
| BP | GO:0050900 | Leukocyte migration | 34/337 | 499/18670 | 2.23E−09 | 2.10E−09 | IGLL1/APOB/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/SIRPG/IGLV2-8/IGLV6-57/IGHV3-53/CCL5/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-70/IGHV1-69/IGLV3-19/MAG/SLC7A10/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/CXCL9/IGLC7/ATP1B2/EDN3/CXCL13/IGHV2-5 | 34 |
| BP | GO:0050727 | Regulation of inflammatory response | 30/337 | 485/18670 | 3.25E−07 | 3.05E−07 | IGHV4-34/IGLV1-44/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/APOA1/IGLV6-57/IGHV3-53/CCL5/GBP5/IGLV3-21/IGHV4-59/IGHV3-23/IGLV2-14/IGHV3-13/IGKV1-5/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLV7-43/IGHV3-30/IGKV1-17/IGKV1D-12/IGKC/LRFN5/IGLC7/IGHG2/IGHV2-5 | 30 |
| BP | GO:0042475 | Odontogenesis of dentin-containing tooth | 10/337 | 90/18670 | 0.000340129 | 0.000319658 | WNT6/KLK4/SCN5A/FGF4/DLX3/BMP2/KLK5/CA2/FGF8/WNT10A | 10 |
| BP | GO:0031128 | Developmental induction | 6/337 | 34/18670 | 0.001891025 | 0.001777212 | SIX3/WNT4/HOXC11/BMP2/FGF8/GDNF | 6 |
| BP | GO:0009952 | Anterior/posterior pattern specification | 14/337 | 219/18670 | 0.002987205 | 0.002807418 | SIX3/HOXC8/HOXC6/ALX1/CRB2/FOXC2/HOXC10/HOXC11/BMP2/FGF8/HOXC9/CDX1/BARX1/NKD1 | 14 |
| BP | GO:0021984 | Adenohypophysis development | 4/337 | 13/18670 | 0.004101352 | 0.003854509 | WNT4/BMP2/FGF8/SOX2 | 4 |
| BP | GO:0003002 | Regionalization | 18/337 | 351/18670 | 0.004611317 | 0.004333781 | SIX3/HOXC8/HOXC6/ALX1/NKX2-2/CRB2/FOXC2/HOXC10/HOXC11/BMP2/FGF8/WNT7A/GDNF/HOXC9/CDX1/BARX1/DMRTA2/NKD1 | 18 |
| BP | GO:0045165 | Cell fate commitment | 15/337 | 270/18670 | 0.007471561 | 0.00702188 | WNT6/WNT4/FOXN1/NKX2-2/WNT16/FOXC2/HOXC10/BMP2/FGF8/TENM4/WNT7A/WNT5B/SOX2/WNT10A/DMRTA2 | 15 |
| BP | GO:0098742 | Cell–cell adhesion via plasma-membrane adhesion molecules | 15/337 | 273/18670 | 0.008281927 | 0.007783474 | PTPRT/APOA1/CLDN9/CRB2/CDH22/BMP2/MAG/LRRC4C/CLDN19/PCDH10/TENM4/CLDN6/TRO/PCDHB5/LRFN5 | 15 |
| BP | GO:0042476 | Odontogenesis | 10/337 | 132/18670 | 0.008307838 | 0.007807825 | WNT6/KLK4/SCN5A/FGF4/DLX3/BMP2/KLK5/CA2/FGF8/WNT10A | 10 |
| BP | GO:0061844 | Antimicrobial humoral immune response mediated by antimicrobial peptide | 7/337 | 73/18670 | 0.01961805 | 0.018437324 | REG1A/KLK7/KLK3/CAMP/KLK5/CXCL9/CXCL13 | 7 |
| BP | GO:0007389 | Pattern specification process | 19/337 | 446/18670 | 0.028662281 | 0.026937221 | SIX3/HOXC8/WNT6/HOXC6/ALX1/NKX2-2/CRB2/FOXC2/HOXC10/HOXC11/BMP2/FGF8/WNT7A/GDNF/HOXC9/CDX1/BARX1/DMRTA2/NKD1 | 19 |
| BP | GO:0001759 | Organ induction | 4/337 | 22/18670 | 0.032449794 | 0.03049678 | HOXC11/BMP2/FGF8/GDNF | 4 |
| BP | GO:0048762 | Mesenchymal cell differentiation | 12/337 | 219/18670 | 0.035439505 | 0.033306553 | ALX1/SOX11/WNT4/FGF19/CRB2/WNT16/FOXC2/BMP2/FGF8/GDNF/EDN3/WNT10A | 12 |
| BP | GO:0001658 | Branching involved in ureteric bud morphogenesis | 6/337 | 59/18670 | 0.035439505 | 0.033306553 | WNT6/ADAMTS16/WNT4/BMP2/FGF8/GDNF | 6 |
| BP | GO:0016338 | Calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules | 4/337 | 23/18670 | 0.036228036 | 0.034047626 | CLDN9/BMP2/CLDN19/CLDN6 | 4 |
| BP | GO:0045109 | Intermediate filament organization | 4/337 | 23/18670 | 0.036228036 | 0.034047626 | TCHH/NEFH/GFAP/KRT71 | 4 |
| BP | GO:0021871 | Forebrain regionalization | 4/337 | 24/18670 | 0.042179675 | 0.039641061 | SIX3/BMP2/FGF8/DMRTA2 | 4 |
| BP | GO:0046886 | Positive regulation of hormone biosynthetic process | 3/337 | 11/18670 | 0.042595197 | 0.040031574 | WNT4/IFNG/PPARGC1A | 3 |
| BP | GO:0048864 | Stem cell development | 7/337 | 85/18670 | 0.042595197 | 0.040031574 | ALX1/SOX11/FGF19/FOXC2/WNT7A/GDNF/EDN3 | 7 |
| BP | GO:0021983 | Pituitary gland development | 5/337 | 42/18670 | 0.044221556 | 0.04156005 | SIX3/WNT4/BMP2/FGF8/SOX2 | 5 |
| BP | GO:0070268 | Cornification | 8/337 | 112/18670 | 0.04586542 | 0.043104977 | TCHH/FLG/KRT71/KRT36/KRT5/KLK5/KRT31/KRT34 | 8 |
| BP | GO:0008211 | Glucocorticoid metabolic process | 4/337 | 25/18670 | 0.04586542 | 0.043104977 | WNT4/APOA1/BMP2/SERPINA6 | 4 |
| CC | GO:0019814 | Immunoglobulin complex | 51/354 | 159/19717 | 1.95E−47 | 1.78E−47 | IGHV4-31/IGLV5-45/IGLL1/IGLV8-61/IGHV4-34/IGKV3D-15/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/IGHJ1/IGKV1-27/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGLV1-36/IGHV3-23/IGHV3-73/IGLV2-14/IGLV4-69/IGHV3-13/IGLV3-16/IGKV1-5/IGKV1D-43/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/IGLV7-43/IGKV1D-13/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/IGKV6D-21/IGKC/IGLC7/IGHV3-74/IGLV7-46/IGLV4-60/IGHG2/IGHV2-5 | 51 |
| CC | GO:0042571 | Immunoglobulin complex, circulating | 26/354 | 72/19717 | 3.37E−-25 | 3.07E−25 | IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 26 |
| CC | GO:0009897 | External side of plasma membrane | 39/354 | 393/19717 | 3.99E−16 | 3.63E−16 | IGHV4-31/IGLL1/IL13RA2/IGHV4-34/IGHM/CNTFR/ULBP2/CCR10/LAG3/LY6G6C/IGHG4/IGHV3-43/GPIHBP1/IGHV3-53/IGHV3-72/CD8A/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/GFRA2/IGHV3-13/GFRA1/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/PCSK9/IGHV3-64/FGF8/IGKC/CXCL9/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 39 |
| CC | GO:0072562 | Blood microparticle | 15/354 | 147/19717 | 5.34E−06 | 4.86E−06 | IGHM/IGKV2-30/IGHG4/APOA1/IGLV3-21/IGHV3-23/IGHV3-13/IGKV1-5/IGHG3/IGKV1-17/IGKV1D-12/IGKC/AMBP/PON1/IGHG2 | 15 |
| CC | GO:0042101 | T cell receptor complex | 11/354 | 127/19717 | 0.001186365 | 0.001080471 | TRBV7-6/CD8A/TRBV4-2/TRAV21/TRDV1/TRBV7-9/TRAV19/TRAV12-1/TRAV14DV4/TRBV4-1/TRAV26-2 | 11 |
| CC | GO:0098802 | Plasma membrane receptor complex | 15/354 | 295/19717 | 0.016378041 | 0.01491615 | GRIK5/CNTFR/TRBV7-6/CD8A/TRBV4-2/TRAV21/TRDV1/BMP2/TRBV7-9/CHRNA3/TRAV19/TRAV12-1/TRAV14DV4/TRBV4-1/TRAV26-2 | 15 |
| MF | GO:0003823 | Antigen binding | 41/300 | 160/17697 | 3.33E−34 | 2.97E−34 | IGHV4-31/IGLL1/IGHV4-34/IGLV1-44/IGHM/IGKV2-30/IGKV5-2/LAG3/IGHG4/IGLV2-8/IGHV3-43/IGLV6-57/IGHV3-53/IGHV3-72/IGHV3-66/IGLV3-21/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGLV2-14/IGHV3-13/IGKV1-5/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLV3-19/IGLL5/TRBV7-9/IGLV7-43/IGHV3-30/IGHV3-64/IGKV1-17/IGKV1D-12/TRAV19/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 41 |
| MF | GO:0034987 | Immunoglobulin receptor binding | 26/300 | 76/17697 | 5.43E−25 | 4.85E−25 | IGHV4-31/IGLL1/IGHV4-34/IGHM/IGHG4/IGHV3-43/IGHV3-53/IGHV3-72/IGHV3-66/IGHV4-59/IGHV3-20/IGHV3-23/IGHV3-73/IGHV3-13/IGHV2-26/IGHG3/IGHV2-70/IGHV1-69/IGLL5/IGHV3-30/IGHV3-64/IGKC/IGLC7/IGHV3-74/IGHG2/IGHV2-5 | 26 |
| MF | GO:0005109 | Frizzled binding | 8/300 | 39/17697 | 3.98E−05 | 3.55E−05 | WNT6/MYOC/WNT4/RSPO4/WNT16/WNT7A/WNT5B/WNT10A | 8 |
| MF | GO:0048018 | Receptor ligand activity | 23/300 | 482/17697 | 0.001065684 | 0.000951118 | WNT4/FGF19/APOA1/REG1A/CCL5/TNFSF9/FGF4/INSL4/SLURP1/IFNG/TRH/FGF20/BMP2/FGF8/CXCL9/WNT7A/GDNF/IL1A/FGF3/IGF2/EDN3/WNT10A/CXCL13 | 23 |
| MF | GO:0005104 | Fibroblast growth factor receptor binding | 5/300 | 25/17697 | 0.00536912 | 0.004791912 | FGF19/FGF4/FGF20/FGF8/FGF3 | 5 |
| MF | GO:0004252 | Serine-type endopeptidase activity | 10/300 | 160/17697 | 0.033673709 | 0.030053615 | KLK4/KLK6/CFD/KLK7/KLK3/GZMH/KLK8/KLK1/KLK5/PCSK9 | 10 |
| MF | GO:0046873 | Metal ion transmembrane transporter activity | 18/300 | 438/17697 | 0.036391745 | 0.032479448 | GRIK5/TTYH1/GPM6A/CACNA1S/SCN5A/KCNE5/LRRC55/KCNJ15/SLC5A8/JPH3/CACNG6/CACNA1I/ATP2A3/SLC6A15/SLC13A5/SCN1A/SLC13A2/ATP1B2 | 18 |
| MF | GO:0022839 | Ion gated channel activity | 15/300 | 334/17697 | 0.037581202 | 0.033541033 | GRIK5/TTYH1/CACNA1S/SCN5A/ANO2/KCNE5/LRRC55/KCNJ15/P2RX2/GABRA3/JPH3/CACNG6/CACNA1I/CHRNA3/SCN1A | 15 |
| MF | GO:0022836 | Gated channel activity | 15/300 | 343/17697 | 0.043831647 | 0.039119522 | GRIK5/TTYH1/CACNA1S/SCN5A/ANO2/KCNE5/LRRC55/KCNJ15/P2RX2/GABRA3/JPH3/CACNG6/CACNA1I/CHRNA3/SCN1A | 15 |
| MF | GO:0070325 | Lipoprotein particle receptor binding | 4/300 | 26/17697 | 0.044441069 | 0.039663429 | APOB/APOA1/PCSK9/SYT1 | 4 |
| MF | GO:0008236 | Serine-type peptidase activity | 10/300 | 182/17697 | 0.049388397 | 0.044078894 | KLK4/KLK6/CFD/KLK7/KLK3/GZMH/KLK8/KLK1/KLK5/PCSK9 | 10 |
| MF | GO:0005343 | Organic acid:sodium symporter activity | 4/300 | 28/17697 | 0.049388397 | 0.044078894 | SLC5A8/SLC6A15/SLC13A5/SLC13A2 | 4 |
| MF | GO:0017171 | Serine hydrolase activity | 10/300 | 186/17697 | 0.049706953 | 0.044363203 | KLK4/KLK6/CFD/KLK7/KLK3/GZMH/KLK8/KLK1/KLK5/PCSK9 | 10 |